Discover the power of real-time signals plus AI
Every contract, funding round, exec hire, and M&A move on Abilita Therapeutics and Finnish Orion Corporation — with verified, ICP-scored contact reveals (email + mobile) on demand.
Trusted by founders, sales teams, recruiters, and investors at firms like BlackRock, Oracle, Kleiner Perkins, and HubSpot.
Abilita Therapeutics and Orion Announce Research Collaboration to Develop Next-Generation Antibody Therapeutics in Oncology and Pain Areas
Contract Type
partnership
San DiegoBiotechnologyTherapeuticsDescription
Abilita Therapeutics, Inc. and Finnish Orion Corporation have entered into a collaboration to leverage Abilita's pioneering EMP™ antibody discovery platform for challenging multi-span membrane protein (MMP) targets, with a focus on oncology and pain. Orion has an option to license an undisclosed Abilita discovery program and select two additional MMP targets for drug discovery over the collaboration period. Abilita has the potential to earn up to $785 million plus royalties on commercial sales